Cigna Group Reports Board Changes and Executive Compensation Updates

Ticker: CI · Form: 8-K · Filed: 2025-06-02T00:00:00.000Z

Sentiment: neutral

Topics: governance, executive-compensation, board-of-directors

Related Tickers: CI

TL;DR

Cigna Group filed an 8-K on 5/30/25 for board and exec comp changes.

AI Summary

On May 30, 2025, The Cigna Group filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing includes information regarding the departure of certain officers and the election of new directors, alongside updates to compensatory plans for key executives. Specific details on the financial impact of these changes were not provided in this initial filing.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategic direction or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically have a low direct risk to the company's overall operations.

Key Players & Entities

FAQ

What specific changes were made to The Cigna Group's board of directors?

The filing indicates the departure of certain officers and the election of new directors, though specific names and the exact number of changes are detailed within the full report.

What is the nature of the updates to executive compensation arrangements?

The 8-K filing mentions updates to compensatory arrangements for certain officers, suggesting revisions to their pay structures or incentive plans.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this filing occurred on May 30, 2025.

What is the principal executive office address for The Cigna Group?

The principal executive offices of The Cigna Group are located at 900 Cottage Grove Road, Bloomfield, Connecticut 06002.

What is the Commission File Number for The Cigna Group?

The Commission File Number for The Cigna Group is 001-38769.

From the Filing

0001140361-25-021143.txt : 20250602 0001140361-25-021143.hdr.sgml : 20250602 20250602170347 ACCESSION NUMBER: 0001140361-25-021143 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250530 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250602 DATE AS OF CHANGE: 20250602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance EIN: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 251015972 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 ef20050060_8-k.htm 8-K false 0001739940 NYSE 0001739940 2025-05-30 2025-05-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025   The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.) 900 Cottage Grove Road Bloomfield , Connecticut 06002 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 860 ) 226-6000 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 30, 2025, the board of directors (the “Board”) of The Cigna Group (the “Company”) appointed Michael J. Hennigan as an independent member of the Board, effective June 2, 2025. Mr. Hennigan will participate in the Company’s non-employee director compensation program, amended and restated effective July 24, 2024 (the “Plan”), as described in the Company’s Proxy Statement for the 2025 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission (the &

View on Read The Filing